Mechanism, plainly
How Ipamorelin Works in the Research
What does ipamorelin peptide do, step by step — and how its mechanism differs from GHRH analogs like sermorelin and tesamorelin.
The short version
What does ipamorelin peptide do? In plain terms: it presses one specific button in the pituitary gland to release a short burst of growth hormone. The button is GHS-R1a — the ghrelin receptor, normally triggered by the body's natural hunger hormone. Ipamorelin is a synthetic copy of that signal, built to be stable and selective: it gets the growth-hormone burst without much of the cortisol (stress hormone) or prolactin spillover that older peptides cause [1]. Because it pushes a different button than sermorelin or tesamorelin (which copy a different hormone, GHRH), it can be paired with them. The result is a single, clean growth-hormone pulse that peaks about 40 minutes after a dose and clears in roughly two hours [2].
What is ipamorelin peptide
What is ipamorelin peptide: it is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — designed to mimic ghrelin's action at the GHS-R1a receptor [1]. It was derived from the earlier peptide GHRP-1 by removing a central two-amino-acid segment, and it uses non-natural building blocks (alpha-aminoisobutyric acid, plus D-form amino acids) that make it resistant to the enzymes that would normally chew up a peptide. It is not an endogenous human peptide; it is a copy of a natural signal, engineered for selectivity and stability. Its defining trait is that selectivity — strong growth-hormone release, minimal stress-hormone spillover [1].
Step by step: receptor to pulse
The sequence is specific. Ipamorelin binds GHS-R1a on pituitary somatotrophs — the cells that store and release growth hormone. Binding activates a Gq/phospholipase-C signaling cascade, which raises calcium inside the cell, and the calcium rise triggers growth hormone to be released as a discrete pulse [1]. In humans, that pulse peaks around 40 minutes after dosing and the molecule clears with a roughly two-hour half-life [2]. The selectivity is the engineered part: in rats and swine, ipamorelin matched GHRP-6's growth-hormone potency yet left ACTH and cortisol near baseline even above 200× its growth-hormone threshold [1]. It also reaches beyond the pituitary — acting directly on pancreatic tissue to release insulin in rat studies [11] — but the headline action is the pituitary growth-hormone pulse.
Ipamorelin vs sermorelin
Ipamorelin vs sermorelin comes down to which receptor each one uses. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — it copies the hunger-hormone signal to release growth hormone [1]. Sermorelin is a GHRH analog — it copies growth-hormone-releasing hormone and works through the entirely separate GHRH receptor. Because they act through different doors, their effects on growth-hormone release are complementary rather than redundant, which is why a ghrelin-receptor agonist like ipamorelin is often paired with a GHRH analog. Ipamorelin's distinguishing feature within its own class is selectivity: minimal cortisol and prolactin spillover compared with older ghrelin-receptor peptides [1]. Neither compound is FDA-approved for the uses discussed here.
Ipamorelin vs tesamorelin
Ipamorelin vs tesamorelin is the same receptor distinction, with one regulatory difference. Tesamorelin, like sermorelin, is a GHRH analog acting on the GHRH receptor; ipamorelin acts on the ghrelin receptor (GHS-R1a) [1]. The two therefore raise growth hormone through different, additive pathways. The key contrast: tesamorelin is an approved drug for one specific indication (HIV-associated lipodystrophy), whereas ipamorelin has never been approved for anything and its only Phase 2 human trial missed its endpoint [3]. So they differ both mechanistically (ghrelin receptor versus GHRH receptor) and in regulatory status (unapproved versus approved-for-one-use).